KR102867256B1 - 프로그램 가능한 면역세포 수용체 복합체 시스템 - Google Patents

프로그램 가능한 면역세포 수용체 복합체 시스템

Info

Publication number
KR102867256B1
KR102867256B1 KR1020207029506A KR20207029506A KR102867256B1 KR 102867256 B1 KR102867256 B1 KR 102867256B1 KR 1020207029506 A KR1020207029506 A KR 1020207029506A KR 20207029506 A KR20207029506 A KR 20207029506A KR 102867256 B1 KR102867256 B1 KR 102867256B1
Authority
KR
South Korea
Prior art keywords
cell
cells
programmable
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207029506A
Other languages
English (en)
Korean (ko)
Other versions
KR20210018196A (ko
Inventor
위안위안 탕
조셉 디. 키틀
조엘 에스. 르완드
성원 롄
Original Assignee
펀다멘탈 솔류션스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펀다멘탈 솔류션스 코포레이션 filed Critical 펀다멘탈 솔류션스 코포레이션
Priority to KR1020257032463A priority Critical patent/KR20250151559A/ko
Publication of KR20210018196A publication Critical patent/KR20210018196A/ko
Application granted granted Critical
Publication of KR102867256B1 publication Critical patent/KR102867256B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dermatology (AREA)
KR1020207029506A 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템 Active KR102867256B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257032463A KR20250151559A (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643378P 2018-03-15 2018-03-15
US62/643,378 2018-03-15
US201862651916P 2018-04-03 2018-04-03
US62/651,916 2018-04-03
PCT/US2019/022245 WO2019178342A1 (en) 2018-03-15 2019-03-14 Programmable immunocyte receptor complex system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257032463A Division KR20250151559A (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템

Publications (2)

Publication Number Publication Date
KR20210018196A KR20210018196A (ko) 2021-02-17
KR102867256B1 true KR102867256B1 (ko) 2025-10-01

Family

ID=67905164

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207029506A Active KR102867256B1 (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템
KR1020257032463A Pending KR20250151559A (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257032463A Pending KR20250151559A (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템

Country Status (6)

Country Link
US (3) US20190284255A1 (cg-RX-API-DMAC7.html)
EP (1) EP3765093A4 (cg-RX-API-DMAC7.html)
JP (1) JP7462578B2 (cg-RX-API-DMAC7.html)
KR (2) KR102867256B1 (cg-RX-API-DMAC7.html)
CN (1) CN112955184A (cg-RX-API-DMAC7.html)
WO (1) WO2019178342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11117936B2 (en) * 2017-11-10 2021-09-14 University of Pittsburg—Of the Commonwealth System of Higher Education Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
WO2019178342A1 (en) 2018-03-15 2019-09-19 Fundamental Solutions Corporation Programmable immunocyte receptor complex system
AU2020325225A1 (en) * 2019-08-05 2022-03-24 Cartherics Pty. Ltd. Immune cells expressing modified cell receptors and methods of making

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874239A (en) 1993-07-30 1999-02-23 Affymax Technologies N.V. Biotinylation of proteins
GB9721075D0 (en) * 1997-10-03 1997-12-03 Cancer Res Campaign Tech Materials and methods relating to the stimulation of cells
FI20021518A0 (fi) * 2002-08-23 2002-08-23 Jyvaeskylaen Yliopisto Avidiinin lämpökestävyyden lisääminen
US9708384B2 (en) * 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
KR20150029714A (ko) * 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
NZ759969A (en) * 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
PL3212225T3 (pl) * 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
US9752199B2 (en) 2015-03-31 2017-09-05 Fundamental Solutions Corporation Biosensor system for the rapid detection of analytes
IL254687B2 (en) * 2015-03-31 2024-01-01 Fundamental Solutions Corp Biosensor system for the rapid detection of analytes
US20180161369A1 (en) * 2015-05-29 2018-06-14 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
US12121539B2 (en) * 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
WO2019178342A1 (en) 2018-03-15 2019-09-19 Fundamental Solutions Corporation Programmable immunocyte receptor complex system

Also Published As

Publication number Publication date
WO2019178342A1 (en) 2019-09-19
KR20210018196A (ko) 2021-02-17
JP2021518428A (ja) 2021-08-02
KR20250151559A (ko) 2025-10-21
US20250197472A1 (en) 2025-06-19
CN112955184A (zh) 2021-06-11
EP3765093A1 (en) 2021-01-20
JP7462578B2 (ja) 2024-04-05
EP3765093A4 (en) 2021-12-08
US20200299352A1 (en) 2020-09-24
US20190284255A1 (en) 2019-09-19
US12234273B2 (en) 2025-02-25

Similar Documents

Publication Publication Date Title
US11266690B2 (en) Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
AU2022201263B2 (en) Chimeric antigen receptors and uses thereof
US20210236650A1 (en) Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
AU2019275479B2 (en) Chimeric antigen receptors with modified linker domains and uses thereof
US9249217B2 (en) Bispecific EGFRvIII x CD3 antibody engaging molecules
US20250197472A1 (en) Programmable immunocyte receptor complex system
US10053514B2 (en) Human bispecific EGFRvIII and CD3 antibody engaging molecules
CN115175929A (zh) 活性增强的bcma car-t细胞
US9676858B2 (en) Human bispecific EGFRvIII antibody and CD3 engaging molecules
AU2020332969A1 (en) Anti-PD-L1 single domain antibodies
AU2017209313A1 (en) ROR2 antibody compositions and related methods
KR20230126713A (ko) Cea6 결합 분자 및 이의 사용
US20260007749A1 (en) Chimeric antigen receptor with increased affinity for mesothelin and use thereof
KR20220122844A (ko) Cd22에 특이적인 인간화 항체 및 이의 용도
US20250213691A1 (en) Antigen binding protein targeting msln and use thereof
EP4286520A1 (en) Antigen binding protein and use thereof
CN116284389A (zh) 抗afp/hla02 tcr样抗体及其用途
CN119529098B (zh) 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白
EP4620974A1 (en) Anti-afp/hla02 tcr-like antibody and use thereof
RU2784586C2 (ru) Человеческие антитела, связывающиеся с ror2
WO2024088371A1 (zh) 靶向msln的抗原结合蛋白
HK40067100A (en) Humanized antibody specific for cd22 and chimeric antigen receptor using the same
CN121511260A (zh) SLC4A4/NBCe1抑制剂
HK40084006A (zh) 活性增强的bcma car-t细胞

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)